Company: CDLX
Filing Date: 2025-04-03
Form Type: ARS
Source: 0001666071-25-000048
Chunk: 102

Company: Cardlytics, Inc.
Filing Date: 2025-04-03
Form: ARS
Chunk 102
---
-term contingent consideration — 4,162 Other long-term liabilities — 73 Total liabilities 322,718 439,346 Commitments and contingencies (Note 13) Stockholders’ equity: Common stock, $0.0001 par value—100,000 shares authorized and 51,257 and 39,728 shares issued and outstanding as of December 31, 2024 and December 31, 2023, respectively 10 9 Additional paid-in capital 1,366,958 1,243,594 Accumulated other comprehensive income 3,601 2,467 Accumulated deficit (1,300,576) (1,111,272) Total stockholders’ equity 69,993 134,798 Total liabilities and stockholders’ equity $ 392,711 $ 574,144 December 31, See notes to the consolidated financial statements 64

CARDLYTICS, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Amounts in thousands, except per share amounts) Year Ended December 31, 2024 2023 2022 Revenue $ 278,298 $ 309,204 $ 298,542 Costs and expenses: Partner Share and other third-party costs 127,761 150,578 155,507 Delivery costs 29,643 28,248 30,403 Sales and marketing expense 52,649 57,425 74,745 Research and development expense 49,607 51,352 54,435 General and administrative expense 56,482 58,810 81,446 Acquisition, integration and divestiture costs (benefits) 161 (6,313) (2,874) Change in contingent consideration 210 1,246 (128,174) Impairment of goodwill and intangible assets 131,595 70,518 453,288 Loss on divestiture — 6,550 — Depreciation and amortization expense 25,689 26,460 37,544 Total costs and expenses 473,797 444,874 756,320 Operating loss (195,499) (135,670) (457,778) Other income (expense): Interest expense, net (5,553) (2,336) (2,556) Foreign currency (loss) gain (1,269) 3,304 (6,376) Gain on debt extinguishment 13,017 — — Total other income (expense) 6,